Switch to:
More From Other Websites
HALOZYME THERAPEUTICS INC Financials Aug 19 2014
Halozyme Gains on Narrower-than-Expected Loss, Revenues Up Aug 14 2014
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2014
Halozyme Reports Second Quarter 2014 Financial Results Aug 11 2014
Q2 2014 Halozyme Therapeutics, Inc. Earnings Release - After Market Close Aug 11 2014
Halozyme to Host second Quarter 2014 Financial Results Conference Call Aug 04 2014
Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's "Perilous Reversal" Stock Aug 01 2014
Halozyme Therapeutics Receives Favorable FDA Decision Jul 31 2014
FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter’s HyQvia for Primary... Jul 31 2014
FDA panel: Benefit of Baxter's immune therapy outweighs risk Jul 31 2014
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer Jul 22 2014
Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's "Perilous Reversal" Stock Jul 21 2014
BUZZ-U.S. Stocks on the Move-Isle of Capri, Intercloud, Rent-A-Center Jul 11 2014
Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer... Jul 08 2014
Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme Jun 25 2014
Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference Jun 17 2014
Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th... Jun 15 2014
Halozyme Therapeutics (HALO) In A Perilous Reversal Jun 13 2014
Halozyme Therapeutics upgraded by UBS Jun 12 2014
The Zacks Analyst Blog Highlights: Clovis, Biogen, Halozyme, Ariad and Chart Industries Jun 12 2014
Why Halozyme Therapeutics Was Upgraded To 'Buy' This Morning Jun 12 2014
Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted Jun 11 2014
Ahead of the Bell: Halozyme Therapeutics soars Jun 05 2014
Ahead of the Bell: Halozyme Therapeutics rallies May 13 2014
Halozyme tumbles after company pauses study Apr 04 2014
Halozyme Announces Roche Marketing Authorization For MabThera SC For Patients With Common Forms Of... Mar 28 2014
Halozyme Announces Positive Results From Phase 1/2 Clinical Trial In Cellulite With HTI-501 Mar 25 2014
Halozyme Therapeutics To Present At The Barclays 2014 Global Healthcare Conference Mar 05 2014
Halozyme Reports Fourth Quarter And Year End 2013 Financial Results Feb 27 2014
Halozyme Therapeutics To Present At The Cowen And Company 34th Annual Healthcare Conference Feb 25 2014
Halozyme to Host Fourth Quarter and 2013 Year-End Financial Results Conference Call Feb 20 2014
Halozyme Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of... Feb 10 2014
Halozyme Therapeutics Prices Public Offering Of Common Stock Feb 04 2014
Halozyme Therapeutics Announces Public Offering Of Common Stock Feb 03 2014
Halozyme Therapeutics Provides an Update on Anticipated Milestones for 2014 at the 32nd Annual J. P.... Jan 13 2014
Halozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference Jan 09 2014
Halozyme Secures Additional $20 Million Term Loan Jan 06 2014
Halozyme Therapeutics Announces Executive Transitions Dec 17 2013
Baxter Submits Amended BLA to U.S. FDA for HyQvia for Primary Immunodeficiency Dec 02 2013
Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference Nov 26 2013
Halozyme Reports Third Quarter 2013 Financial Results Nov 08 2013
Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference Nov 06 2013
Halozyme to Host Third Quarter 2013 Financial Results Conference Call Nov 01 2013
MARKET PULSE-Microsoft, Amgen, Verizon, coal producers, homebuilders Sep 03 2013
MARKET PULSE-Microsoft, Amgen, Verizon, Nokia, coal producers, Isis Sep 03 2013
MARKET PULSE-Microsoft, Amgen, Verizon, Nokia, coal producers, Isis Sep 03 2013
MARKET PULSE-Microsoft, Amgen, Verizon, Nokia, coal producers Sep 03 2013


Add Notes, Comments or Ask Questions

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK